Piramal Pharma’s division launches Chlorpromazine Hydrochloride for Injection, USP

23 Jan 2025 Evaluate

Piramal Pharma’s division -- Piramal Critical Care (PCC) has launched Chlorpromazine Hydrochloride for Injection, USP, which will be offered in 25mg/1mL and 50mg/2 mL vials. With this launch, PCC continues to expand their generic injectables portfolio. 

The launch of Chlorpromazine Hydrochloride for Injection, USP (25mg/1mL and 50mg/2 mL vials) is the latest in a series of recent product launches from Piramal Critical Care in the generic injectables market. In 2024, PCC launched the first to market generic of Edaravone IV Infusion, which followed 2023 launches of Pantoprazole Sodium for Injection, USP and Doxycycline for Injection, USP to further enhance their wide portfolio of critical care products.

Piramal Pharma provides end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network.

Piramal Pharma Share Price

226.00 0.40 (0.18%)
02-Apr-2025 09:50 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1714.25
Dr. Reddys Lab 1149.75
Cipla 1452.70
Lupin 2009.40
Zydus Lifesciences 891.25
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Please wait your portfolio is updating...